靶向治疗HER2阳性乳腺癌患者的新型抗体药物偶联物:T-DM1与T-DXd

A new type of antibody drug conjugate targeting HER2 therapy for breast cancer:T-DM1 and T-DXd

抗体药物偶联物是一类很有前景的药物,它利用单克隆抗体的特异性,选择性地将所连接的细胞毒类药物递送至肿瘤细胞内,通过增加抗肿瘤活性和降低脱靶毒性来达到更好的治疗效果。随着肿瘤精准治疗时代的到来,恩美曲妥珠单抗(T-DM1)与德曲妥珠单抗(T-DXd)为HER2阳性乳腺癌患者带来了巨大希望,也开启了HER2过表达及低表达乳腺癌患者治疗的新征程。本文就这两种药物的作用机制、适应证、有效性及安全性等方面进行论述,对临床合理使用提供参考。

Antibody drug conjugate is a promising class of drugs that utilize the specificity of monoclonal antibodies to selectively deliver the attached cytotoxic small molecules to the inside of tumor cells,achieving better results by increasing anti-tumor activity and decreasing off-target toxicity.With the advent of the era of precision tumor therapy,trastuzumab emtansine(T-DM1)and trastuzumab deruxtecan(T-DXd)have brought great hope for patients with human epidermal growth factor receptor 2 positive breast cancer,opening up a new phase in the treatment of HER2 overexpressing breast cancer and even some HER2 low-expressing breast cancer.This review discussed the mechanism of action,indication,efficacy and safety of T-DM1 and T-DXd,which may have an important guiding role for rational drug use.